Nebivolol

Nebivolol is a beta-blocker taken by mouth. The US label read, for Bystolic, lists one use: the treatment of hypertension, to lower blood pressure.

Also called Bystolic

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 31555; UNII JGS34J7L9I. The label names the substance as nebivolol hydrochloride, so UNII JGS34J7L9I is the UNII of the hydrochloride salt and is a broad match. MeSH descriptor D000068577 is Nebivolol. Class: beta-Adrenergic Blocker (FDA established pharmacologic class, RxClass). The label read is the Allergan, Inc. label for BYSTOLIC (nebivolol hydrochloride), application NDA021742, effective 2024-08-01 in openFDA. Other nebivolol labels in openFDA, from generic sponsors, were not read. This page records label indications and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 6 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
6
Phase 3 or 4
5
Recruiting
1
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseRecruitingNot yet recruitingActive, not recruitingCompletedAll statuses
Phase 2/310001
Phase 401135
All phases11136

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

About this drug

Level
Substance
Mechanism
Not reported

Classification codes

  • UNII JGS34J7L9I

Claims and evidence

Context People for whom the US label of nebivolol (Bystolic) lists an indication: hypertension

Recipient
Recipient not specified
Population
Patients described in the indications section of the label. The label does not state an age range in the passage read.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passage read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of BYSTOLIC (nebivolol hydrochloride), in the Allergan, Inc. version dated 2024-08-01 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure.

    Applies to Recipient not specified People for whom the US label of nebivolol (Bystolic) lists an indication: hypertension

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-08
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for BYSTOLIC (nebivolol hydrochloride), Allergan, Inc. label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 8b8ad213-1dc8-454e-a524-075685c0e1a8 (manufacturer Allergan, Inc., application NDA021742), returned on 2026-11-08. The label text is dated 2024-08-01 (effective_time). Other openFDA records of nebivolol labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1. INDICATIONS AND USAGE
      How it applies
      The label sentences that give the indications named in the statement, each quoted in the research quote table.
      Retrieved
      Source effective date
      2024-08-01
      Source state
      Current
      Version fingerprint
      272454333965f93512f2cc1866c29f068170de6a24c0b87238d21dba3f07fdef
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-08, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for BYSTOLIC (nebivolol hydrochloride), Allergan, Inc. label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 8b8ad213-1dc8-454e-a524-075685c0e1a8 (manufacturer Allergan, Inc., application NDA021742), returned on 2026-11-08. The label text is dated 2024-08-01 (effective_time). Other openFDA records of nebivolol labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20240801.
      Retrieved
      Source effective date
      2024-08-01
      Source state
      Current
      Version fingerprint
      272454333965f93512f2cc1866c29f068170de6a24c0b87238d21dba3f07fdef
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-08, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

BYSTOLIC

No label from the application holder was found in the openFDA label dataset for application NDA021742. This page does not show another labeler's label in its place.

BYVALSON

No label from the application holder was found in the openFDA label dataset for application NDA206302. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA021742 BYSTOLIC
  2. Supplemental approval NDA021742 BYSTOLIC
  3. Approval NDA206302 BYVALSON

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 2

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.

    ProductNDA021742

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA206302

Registry trials 6

Record details

Record id
cardio:nebivolol
Content hash
df4cc2591bc44831f9e9406b778f2108f4b8fd17d652d888c7c10c41486e36cd